Published in J Immunol on May 01, 1998
Complement C3 activation is required for antiphospholipid antibody-induced fetal loss. J Exp Med (2002) 2.09
Targeted complement inhibition by C3d recognition ameliorates tissue injury without apparent increase in susceptibility to infection. J Clin Invest (2005) 1.70
A novel targeted inhibitor of the alternative pathway of complement and its therapeutic application in ischemia/reperfusion injury. J Immunol (2008) 1.70
Complement receptor 2-mediated targeting of complement inhibitors to sites of complement activation. J Clin Invest (2003) 1.46
Anti-C1q autoantibodies deposit in glomeruli but are only pathogenic in combination with glomerular C1q-containing immune complexes. J Clin Invest (2004) 1.31
Crk1/2-dependent signaling is necessary for podocyte foot process spreading in mouse models of glomerular disease. J Clin Invest (2012) 1.25
Targeting pathogenic postischemic self-recognition by natural IgM to protect against posttransplantation cardiac reperfusion injury. Circulation (2015) 1.16
Transgenic mice overexpressing the complement inhibitor crry as a soluble protein are protected from antibody-induced glomerular injury. J Exp Med (1998) 1.08
IL-15, a survival factor for kidney epithelial cells, counteracts apoptosis and inflammation during nephritis. J Clin Invest (2002) 1.03
Complement regulates TLR4-mediated inflammatory responses during intestinal ischemia reperfusion. Mol Immunol (2010) 0.99
Coupling complement regulators to immunoglobulin domains generates effective anti-complement reagents with extended half-life in vivo. Clin Exp Immunol (2002) 0.97
Targeting of functional antibody-CD59 fusion proteins to a cell surface. J Clin Invest (1999) 0.96
Comparative functional evolution of human and mouse CR1 and CR2. J Immunol (2008) 0.95
Complement factor B is the downstream effector of TLRs and plays an important role in a mouse model of severe sepsis. J Immunol (2013) 0.93
Poly(ADP-ribose) polymerase-1 regulates the progression of autoimmune nephritis in males by inducing necrotic cell death and modulating inflammation. J Immunol (2009) 0.92
Urine proteome analysis in murine nephrotoxic serum nephritis. Am J Nephrol (2009) 0.90
Transient receptor potential channel 6 (TRPC6) protects podocytes during complement-mediated glomerular disease. J Biol Chem (2013) 0.89
The benefit of targeted and selective inhibition of the alternative complement pathway for modulating autoimmunity and renal disease in MRL/lpr mice. Arthritis Rheum (2011) 0.89
Prevention of experimental autoimmune myasthenia gravis by rat Crry-Ig: A model agent for long-term complement inhibition in vivo. Mol Immunol (2007) 0.88
Theodore E. Woodward Award: antiphospholipid syndrome revisited: a disorder initiated by inflammation. Trans Am Clin Climatol Assoc (2007) 0.86
The role of the complement system in acute kidney injury. Semin Nephrol (2013) 0.83
Production and functional analysis of rat CD59 and chimeric CD59-Crry as active soluble proteins in Pichia pastoris. Immunology (2000) 0.83
Protective effect of scFv-DAF fusion protein on the complement attack to acetylcholine receptor: a possible option for treatment of myasthenia gravis. Muscle Nerve (2012) 0.83
Review: Complement and its regulatory proteins in kidney diseases. Nephrology (Carlton) (2010) 0.82
Suppression of complement activation by recombinant Crry inhibits experimental autoimmune anterior uveitis (EAAU). Mol Immunol (2010) 0.81
Human diffusely adhering Escherichia coli expressing Afa/Dr adhesins that use human CD55 (decay-accelerating factor) as a receptor does not bind the rodent and pig analogues of CD55. Infect Immun (2004) 0.78
Anti-C1q autoantibodies amplify pathogenic complement activation in systemic lupus erythematosus. J Clin Invest (2004) 0.78
Modulation of post-stroke degenerative and regenerative processes and subacute protection by site-targeted inhibition of the alternative pathway of complement. J Neuroinflammation (2015) 0.77
Mesangial cell complement receptor 1-related protein y limits complement-dependent neutrophil accumulation in immune complex glomerulonephritis. Immunology (2009) 0.77
Pathophysiology of the antiphospholipid antibody syndrome. Auto Immun Highlights (2011) 0.76
An allelic variant of Crry in the murine Sle1c lupus susceptibility interval is not impaired in its ability to regulate complement activation. J Immunol (2010) 0.76
sIgM-FcμR Interactions Regulate Early B Cell Activation and Plasma Cell Development after Influenza Virus Infection. J Immunol (2017) 0.75
Genome sequence of enterohaemorrhagic Escherichia coli O157:H7. Nature (2001) 23.49
LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science (2003) 19.77
CCR7 coordinates the primary immune response by establishing functional microenvironments in secondary lymphoid organs. Cell (1999) 12.50
Follicular B helper T cells express CXC chemokine receptor 5, localize to B cell follicles, and support immunoglobulin production. J Exp Med (2000) 6.57
A putative chemokine receptor, BLR1, directs B cell migration to defined lymphoid organs and specific anatomic compartments of the spleen. Cell (1996) 5.97
Detection of Epstein-Barr virus in invasive breast cancers. J Natl Cancer Inst (1999) 4.94
Experimental glomerulonephritis in the isolated perfused rat kidney. J Clin Invest (1978) 4.45
egc, a highly prevalent operon of enterotoxin gene, forms a putative nursery of superantigens in Staphylococcus aureus. J Immunol (2001) 4.36
Genome-wide, large-scale production of mutant mice by ENU mutagenesis. Nat Genet (2000) 3.92
Peroxynitrite reductase activity of bacterial peroxiredoxins. Nature (2000) 3.69
In situ immune complex formation and glomerular injury. Kidney Int (1980) 3.52
A critical role for murine complement regulator crry in fetomaternal tolerance. Science (2000) 3.27
Excessive ethanol drinking following a history of dependence: animal model of allostasis. Neuropsychopharmacology (2000) 3.15
Expression of the G-protein--coupled receptor BLR1 defines mature, recirculating B cells and a subset of T-helper memory cells. Blood (1994) 2.93
The Epstein-Barr virus nuclear antigen 2 interacts with an EBNA2 responsive cis-element of the terminal protein 1 gene promoter. EMBO J (1993) 2.74
Markedly impaired humoral immune response in mice deficient in complement receptors 1 and 2. Proc Natl Acad Sci U S A (1996) 2.71
The regulators of complement activation (RCA) gene cluster. Adv Immunol (1989) 2.63
Cloning and characterization of cDNAs encoding the complete sequence of decay-accelerating factor of human complement. Proc Natl Acad Sci U S A (1987) 2.62
Regulation of the B cell response to T-dependent antigens by classical pathway complement. J Immunol (1996) 2.51
B-cell proliferation and induction of early G1-regulating proteins by Epstein-Barr virus mutants conditional for EBNA2. EMBO J (1995) 2.51
Subcellular localization of wild-type and Parkinson's disease-associated mutant alpha -synuclein in human and transgenic mouse brain. J Neurosci (2000) 2.49
Human origin recognition complex binds to the region of the latent origin of DNA replication of Epstein-Barr virus. EMBO J (2001) 2.46
Does changing the configuration of a motor racing circuit make it safer? Br J Sports Med (2005) 2.40
Duration of preclinical rheumatoid arthritis-related autoantibody positivity increases in subjects with older age at time of disease diagnosis. Ann Rheum Dis (2007) 2.38
Low muscle mass and sarcopenia: common and predictive of osteopenia in inflammatory bowel disease. Aliment Pharmacol Ther (2015) 2.34
YACs and the C. elegans genome. Bioessays (1991) 2.33
Intracellular and surface expression of the HIV-1 coreceptor CXCR4/fusin on various leukocyte subsets: rapid internalization and recycling upon activation. J Immunol (1998) 2.22
Discovery of a small molecule insulin mimetic with antidiabetic activity in mice. Science (1999) 2.21
Poly(A) site selection in the HIV-1 provirus: inhibition of promoter-proximal polyadenylation by the downstream major splice donor site. Genes Dev (1995) 2.13
A new role for complement in experimental membranous nephropathy in rats. J Clin Invest (1980) 2.11
Experimental membranous glomerulonephritis in rats. Quantitative studies of glomerular immune deposit formation in isolated glomeruli and whole animals. J Clin Invest (1980) 2.07
Direct detection and identification of Pseudomonas aeruginosa in clinical samples such as skin biopsy specimens and expectorations by multiplex PCR based on two outer membrane lipoprotein genes, oprI and oprL. J Clin Microbiol (1997) 2.04
Switch in chemokine receptor expression upon TCR stimulation reveals novel homing potential for recently activated T cells. Eur J Immunol (1999) 2.01
Expression of complement receptors 1 and 2 on follicular dendritic cells is necessary for the generation of a strong antigen-specific IgG response. J Immunol (1998) 1.96
Implication of gammadelta T cells in the human immune response to cytomegalovirus. J Clin Invest (1999) 1.91
Lack of chemokine receptor CCR1 enhances Th1 responses and glomerular injury during nephrotoxic nephritis. J Clin Invest (1999) 1.84
T cell response to Epstein-Barr virus transactivators in chronic rheumatoid arthritis. J Exp Med (1996) 1.80
Herpes simplex virus glycoproteins gC-1 and gC-2 bind to the third component of complement and provide protection against complement-mediated neutralization of viral infectivity. J Exp Med (1987) 1.74
Mouse complement regulatory protein Crry/p65 uses the specific mechanisms of both human decay-accelerating factor and membrane cofactor protein. J Exp Med (1995) 1.74
Human endogenous retrovirus K10: expression of Gag protein and detection of antibodies in patients with seminomas. J Virol (1995) 1.72
Randomized clinical trial of the impact of early enteral feeding on postoperative ileus and recovery. Br J Surg (2007) 1.69
Novel critical role of a human Mediator complex for basal RNA polymerase II transcription. EMBO Rep (2001) 1.67
Experimental glomerulonephritis. Methods Enzymol (1988) 1.67
Hyperpolarization-activated channels HCN1 and HCN4 mediate responses to sour stimuli. Nature (2001) 1.66
Generation of a humanized, high affinity anti-tissue factor antibody for use as a novel antithrombotic therapeutic. Thromb Haemost (2001) 1.64
Role for erbin in bacterial activation of Nod2. Infect Immun (2006) 1.63
Complement-mediated injury reversibly disrupts glomerular epithelial cell actin microfilaments and focal adhesions. Kidney Int (1999) 1.62
Evidence that chronic lymphocytic leukemia B lymphocytes are frequently committed to production of natural autoantibodies. Blood (1990) 1.58
Identification of latent membrane protein 2A (LMP2A) domains essential for the LMP2A dominant-negative effect on B-lymphocyte surface immunoglobulin signal transduction. J Virol (1996) 1.57
Modulation of renal disease in MRL/lpr mice genetically deficient in the alternative complement pathway factor B. J Immunol (2000) 1.55
The antibody 2B4 directed against the Epstein-Barr virus (EBV)-encoded nuclear antigen 1 (EBNA1) detects MAGE-4: implications for studies on the EBV association of human cancers. J Pathol (2006) 1.55
Identification and characterization of specific DNA-binding complexes containing members of the Myc/Max/Mad network of transcriptional regulators. J Biol Chem (1998) 1.53
Volume of isoflow. A new test in detection of mild abnormalities of lung mechanics. Am Rev Respir Dis (1974) 1.53
The helical domain of GBP-1 mediates the inhibition of endothelial cell proliferation by inflammatory cytokines. EMBO J (2001) 1.53
Increased incidence of acute leukemia in polycythemia vera associated with chlorambucil therapy. N Engl J Med (1981) 1.52
Tyrosine 112 of latent membrane protein 2A is essential for protein tyrosine kinase loading and regulation of Epstein-Barr virus latency. J Virol (1998) 1.52
Analysis of the E-cadherin repressor Snail in primary human cancers. Cells Tissues Organs (2007) 1.52
Nationwide outbreak of listeriosis due to contaminated meat. Epidemiol Infect (2005) 1.52
Mouse Crry/p65. Characterization of monoclonal antibodies and the tissue distribution of a functional homologue of human MCP and DAF. J Immunol (1993) 1.50
Cytotoxic T lymphocyte lysis inhibited by viable HIV mutants. Science (1995) 1.48
A cGMP-signaling pathway in a subset of olfactory sensory neurons. Proc Natl Acad Sci U S A (2000) 1.48
Structural requirements for C3d,g/Epstein-Barr virus receptor (CR2/CD21) ligand binding, internalization, and viral infection. J Biol Chem (1990) 1.48
The umbilical cord blood alphabeta T-cell repertoire: characteristics of a polyclonal and naive but completely formed repertoire. Blood (1998) 1.48
Cloning of rat nephrin: expression in developing glomeruli and in proteinuric states. Kidney Int (2000) 1.47
Distinct receptor and regulatory properties of recombinant mouse complement receptor 1 (CR1) and Crry, the two genetic homologues of human CR1. J Exp Med (1992) 1.46
Immunohistochemical detection of the Epstein-Barr virus-encoded latent membrane protein 2A in Hodgkin's disease and infectious mononucleosis. Blood (1997) 1.45
T-cell repertoires in healthy and diseased human tissues analysed by T-cell receptor beta-chain CDR3 size determination: evidence for oligoclonal expansions in tumours and inflammatory diseases. Res Immunol (1995) 1.44
Small bakeries--a cross-sectional study of respiratory symptoms, sensitization and dust exposure. Occup Med (Lond) (1999) 1.44
Prevention of interferon-stimulated gene expression using microRNA-designed hairpins. Gene Ther (2008) 1.44
In situ detection of the Epstein-Barr virus-encoded nuclear antigen 1 in oral hairy leukoplakia and virus-associated carcinomas. J Pathol (1996) 1.43
Genomic organization and polymorphisms of the human C3d/Epstein-Barr virus receptor. J Biol Chem (1989) 1.43
Association of rheumatoid arthritis treatment response and disease duration with declines in serum levels of IgM rheumatoid factor and anti-cyclic citrullinated peptide antibody. Arthritis Rheum (2004) 1.43
TRAF6 is a critical mediator of signal transduction by the viral oncogene latent membrane protein 1. EMBO J (2001) 1.42
Mapping of the sites for ligand binding and receptor dimerization at the extracellular domain of the vascular endothelial growth factor receptor FLT-1. J Biol Chem (1997) 1.41
Human endogenous retrovirus protein cORF supports cell transformation and associates with the promyelocytic leukemia zinc finger protein. Oncogene (2000) 1.40
Structure of complement receptor 2 in complex with its C3d ligand. Science (2001) 1.40
Mouse complement receptors type 1 (CR1;CD35) and type 2 (CR2;CD21): expression on normal B cell subpopulations and decreased levels during the development of autoimmunity in MRL/lpr mice. J Immunol (1997) 1.39
Resistance profile of the human immunodeficiency virus type 1 reverse transcriptase inhibitor abacavir (1592U89) after monotherapy and combination therapy. CNA2001 Investigative Group. J Infect Dis (2000) 1.37
Characterization of DP103, a novel DEAD box protein that binds to the Epstein-Barr virus nuclear proteins EBNA2 and EBNA3C. J Biol Chem (1999) 1.37
Acute renal failure due to lymphomatous infiltration of the kidneys. J Am Soc Nephrol (1997) 1.36
Cr2, a candidate gene in the murine Sle1c lupus susceptibility locus, encodes a dysfunctional protein. Immunity (2001) 1.36
Complement-induced glomerular epithelial cell injury. Role of the membrane attack complex in rat membranous nephropathy. J Clin Invest (1986) 1.35
Nephritogenic mAb 5-1-6 is directed at the extracellular domain of rat nephrin. J Clin Invest (1999) 1.33
Role of the terminal complement pathway in experimental membranous nephropathy in the rabbit. J Clin Invest (1983) 1.33
Alpha-synuclein accumulation in a case of neurodegeneration with brain iron accumulation type 1 (NBIA-1, formerly Hallervorden-Spatz syndrome) with widespread cortical and brainstem-type Lewy bodies. Acta Neuropathol (2000) 1.33
A molecular and immunochemical characterization of mouse CR2. Evidence for a single gene model of mouse complement receptors 1 and 2. J Immunol (1990) 1.32
Targeted deletion of CX(3)CR1 reveals a role for fractalkine in cardiac allograft rejection. J Clin Invest (2001) 1.31
Transforming potential of the adenovirus type 5 E4orf3 protein. J Virol (1999) 1.31
Comparison of complementary and alternative medicine use: reasons and motivations between two tertiary children's hospitals. Arch Dis Child (2005) 1.30
A poliovirus neutralization epitope expressed on hybrid hepatitis B surface antigen particles. Science (1986) 1.30
Contribution of the innate immune system to autoimmune myocarditis: a role for complement. Nat Immunol (2001) 1.30
HIV-1 reverse transcriptase (RT) genotype and susceptibility to RT inhibitors during abacavir monotherapy and combination therapy. AIDS (2000) 1.29
The gene encoding decay-accelerating factor (DAF) is located in the complement-regulatory locus on the long arm of chromosome 1. J Exp Med (1987) 1.29
The extracellular domain of CD83 inhibits dendritic cell-mediated T cell stimulation and binds to a ligand on dendritic cells. J Exp Med (2001) 1.28
The luminal part of the murine cytomegalovirus glycoprotein gp40 catalyzes the retention of MHC class I molecules. EMBO J (2000) 1.28